Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1898976 | 1.00 | KDM4E (0.35) | KDM4EMAPK1HSD17B10LMNAALDH1A1 | |
| SCHEMBL1900693 | 0.85 | KDM4E (0.36) | KDM4EMAPK1HSD17B10LMNAALDH1A1 | |
| SCHEMBL1900697 | 0.85 | KDM4E (0.36) | KDM4EMAPK1HSD17B10LMNAALDH1A1 | |
| SCHEMBL1900436 | 0.78 | ALDH1A1 (0.37) | KDM4EMAPK1HSD17B10LMNAALDH1A1 | |
| SCHEMBL1900433 | 0.78 | ALDH1A1 (0.37) | KDM4EMAPK1HSD17B10LMNAALDH1A1 | |
| SCHEMBL3338949 | 0.75 | ADORA3 (0.34) | KDM4EMAPK1 | |
| SCHEMBL3338938 | 0.75 | ADORA3 (0.34) | KDM4EMAPK1 | |
| SCHEMBL20614361 | 0.67 | PDE10A (0.37) | KDM4EMAPK1HSD17B10LMNAHTT | |
| SCHEMBL1898608 | 0.65 | MAPK1 (0.34) | KDM4EMAPK1HSD17B10LMNAHTT | |
| SCHEMBL23524631 | 0.64 | MEN1 (0.38) | MAPK1HSD17B10ALDH1A1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044062-B2 | Substituted pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors of phospatidylinositol 3-kinase alpha | EXELIXIS, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-20110237608-A1 | Pyridopyrimidinone Inhibitors of PI3Kalpha | EXELIXIS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| EP-2322523-A1 | Pyridopyrimidinone Inhibitors of PI3Kalpha | Exelixis, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237608-A1 | Pyridopyrimidinone Inhibitors of PI3Kalpha | PIK3CA, PIK3CD, PIK3CB | KDM4E 2601/4885MAPK1 87/4885HSD17B10 1411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.